GlobeNewswire: Immuron Limited Contains the last 10 of 58 releaseshttp://www.globenewswire.com/External?Length=42019-03-21T17:45:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)http://www.globenewswire.com/news-release/2019/01/29/1706954/0/en/Travelan-FY19-1st-Half-Update-and-Geographic-Expansion-into-North-America.html?f=22&fvtc=4&fvtv=27652Travelan® FY19 1st Half Update and Geographic Expansion into North America2019-01-29T14:30:00Z<![CDATA[Key Highlights:]]>http://www.globenewswire.com/news-release/2019/01/08/1681791/0/en/Immuron-Receives-1-19M-R-D-Tax-Concession-Refund.html?f=22&fvtc=4&fvtv=27652Immuron Receives $1.19M R&D Tax Concession Refund2019-01-08T07:32:05Z<![CDATA[MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of $1.19 million for eligible research and development expenditure incurred during the 2018 Financial Year.]]>http://www.globenewswire.com/news-release/2018/11/19/1653758/0/en/Immuron-Appoints-Gary-S-Jacob-Ph-D-Experienced-US-Based-Biotechnology-Executive-as-CEO.html?f=22&fvtc=4&fvtv=27652Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO2018-11-19T14:00:00Z<![CDATA[MELBOURNE, Australia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Immuron Limited, (IMC or the Company), (ASX: IMC; NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive Officer. Dr Jacob is the former Chairman, President and Chief Executive Officer of Synergy Pharmaceuticals Inc. a Nasdaq-listed public biopharmaceutical company located in New York, NY focused on the development of drugs to treat gastrointestinal disorders and diseases.]]>http://www.globenewswire.com/news-release/2018/11/09/1648817/0/en/NASH-clinical-trial-presentation-and-continued-revenue-growth.html?f=22&fvtc=4&fvtv=27652NASH clinical trial presentation and continued revenue growth2018-11-09T11:00:00Z<![CDATA[Key Highlights:]]>http://www.globenewswire.com/news-release/2018/09/05/1565797/0/en/US-Department-of-Defense-Reports-Travelan-Protects-Against-Shigella-in-Primates.html?f=22&fvtc=4&fvtv=27652US Department of Defense Reports Travelan Protects Against Shigella in Primates2018-09-05T14:00:00Z<![CDATA[Key Highlights:]]>http://www.globenewswire.com/news-release/2018/07/25/1541999/0/en/Immuron-Reports-Record-Revenue-Exceeding-AU-2-million-for-the-FY18-year.html?f=22&fvtc=4&fvtv=27652Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year2018-07-25T14:00:00Z<![CDATA[Key Highlights:]]>http://www.globenewswire.com/news-release/2018/07/24/1541059/0/en/Immuron-Announces-it-has-Received-a-European-Patent-Grant-for-NASH-treatment.html?f=22&fvtc=4&fvtv=27652Immuron Announces it has Received a European Patent Grant for NASH treatment2018-07-24T10:30:04Z<![CDATA[MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The Company is pleased to announce that the European Patent Office (EPO) has decided to Grant a patent for the use of a composition for the treatment of Non-alcoholic steatohepatitis (NASH). This patent (EPO Grant No. 2424890) is entitled “Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder”). This patent is due to Expire in April 2030, with potential for supplementary protection and extension of this monopoly.]]>http://www.globenewswire.com/news-release/2018/07/24/1541058/0/en/US-Department-of-Defense-Research-Collaboration-Moves-Forward.html?f=22&fvtc=4&fvtv=27652US Department of Defense Research Collaboration Moves Forward2018-07-24T10:28:55Z<![CDATA[Key Highlights:]]>http://www.globenewswire.com/news-release/2018/06/26/1529292/0/en/Immuron-Announces-Board-Appointment.html?f=22&fvtc=4&fvtv=27652Immuron Announces Board Appointment2018-06-26T00:36:39Z<![CDATA[MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC), is pleased to announce the appointment of New York based Mr. Richard Jay Berman to serve as a Director of the Company effective from 1 July 2018.]]>http://www.globenewswire.com/news-release/2018/05/08/1498000/0/en/Immuron-Reports-Significant-Alleviation-of-Colitis-Symptoms-in-Preclinical-Program.html?f=22&fvtc=4&fvtv=27652Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program2018-05-08T01:43:59Z<![CDATA[Results confirm LPS Antagonist action of IMM-124E offers a novel therapeutic approach to induce or maintain remission in IBD Results confirm LPS Antagonist action of IMM-124E offers a novel therapeutic approach to induce or maintain remission in IBD]]>